focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 11,600.00
Ask: 12,470.00
Change: 0.00 (0.00%)
Spread: 870.00 (7.50%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,110.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - AstraZeneca PLC

22 May 2014 14:15

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION
(a) Identity of the person whose positions/dealings are being disclosed: Wellington Management Company, LLP
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: 21 May 2014
(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer? YES
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security: Ordinary Shares (GB0009895292) and ADRs (US0463531089)
Interests Short Positions
Number % Number %
(1) Relevant securities owned and/or controlled: 65,070,343 shares 5.15 %
(2) Derivatives (other than options):
(3) Options and agreements to purchase/sell:
Total 65,070,343 shares 5.15 %
(b) Rights to subscribe for new securities (including directors’ and other executive options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
Ordinary Shares (GB0009895292) Purchase 520,024 shares 44.1461 GBP
Ordinary Shares (GB0009895292) Purchase 55,504 shares 43.1983 GBP
Ordinary Shares (GB0009895292) Sale 1,014 shares 43.1350 GBP
Ordinary Shares (GB0009895292) Sale 2,339 shares 42.7112 GBP
ADRs (US0463531089) Sale 2,600 Depository Receipts (representing 2,600 shares on a converted basis) 73.6700 USD
(b) Derivatives transactions (other than options)
Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
(ii) Exercising
Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state “none”

None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None
(c) Attachments
Is a Supplemental Form 8 attached? NO
Date of disclosure 22 May 2014
Contact name John D. Norberg
Telephone number 617-790-7265

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel?s website at www.thetakeoverpanel.org.uk.

Copyright Business Wire 2014

Date   Source Headline
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20217:00 amRNSAstraZeneca prices a EUR800m bond offering
26th May 20219:24 amRNSStabilisation Notice
26th May 20217:00 amRNSAstraZeneca prices a $7bn bond offering
25th May 20217:00 amRNSEMTN programme update - publication of Prospectus
21st May 20217:00 amRNSVaxzevria COVID-19 vaccine approved in Japan
18th May 20213:30 pmRNSDirector/PDMR Shareholding
11th May 20212:00 pmRNSResult of AGM
11th May 20211:55 pmRNSShareholders vote in favour of Alexion acquisition
7th May 20217:00 amRNSImfinzi + tremelimumab showed survival in POSEIDON
5th May 20216:30 pmRNSHolding(s) in Company
4th May 20213:00 pmRNSTotal Voting Rights
4th May 20217:00 amRNSFarxiga approved in the US for CKD
30th Apr 20217:00 amRNSAZN: First quarter 2021 results
26th Apr 20217:10 amRNSSelumetinib recommended for EU approval in NF1
26th Apr 20217:05 amRNSTagrisso adjuvant receives positive CHMP opinion
26th Apr 20217:00 amRNSNirsevimab Phase III trial met primary endpoint
16th Apr 202112:00 pmRNSUS clearance of proposed acquisition of Alexion
14th Apr 20217:00 amRNSTagrisso approved in China in early lung cancer
12th Apr 20211:00 pmRNSCircular and notice of general meeting
12th Apr 20217:00 amRNSUpdate on Farxiga COVID-19 DARE-19 Phase III trial
1st Apr 20213:00 pmRNSTotal Voting Rights
30th Mar 202112:15 pmRNSNotice of AGM
25th Mar 20213:00 pmRNSDirector/PDMR Shareholding
25th Mar 20217:00 amRNSAZD1222 US Ph3 primary analysis confirms efficacy
22nd Mar 20217:00 amRNSAstraZeneca US vaccine trial met primary endpoint
16th Mar 20217:05 amRNSDivestment of Viela shareholding completed
16th Mar 20217:00 amRNSUS supply agreement for additional AZD7442 doses
9th Mar 20213:00 pmRNSDirector/PDMR Shareholding
4th Mar 20213:00 pmRNSDesignation of EU home member state
3rd Mar 20217:00 amRNSUS court decision favours Symbicort patents
2nd Mar 20217:00 amRNSFurther update on roxadustat US regulatory review
1st Mar 20213:00 pmRNSTotal Voting Rights
22nd Feb 20217:00 amRNSVoluntary withdrawal Imfinzi US bladder indication
17th Feb 20217:00 amRNSLynparza: IDMC recommend early analysis of OlympiA
16th Feb 202111:15 amRNSFiling of Form 20-F with SEC
15th Feb 20213:00 pmRNSDirector/PDMR Shareholding
15th Feb 202111:00 amRNSAnnual Financial Report
11th Feb 20217:01 amRNSAstraZeneca Non-Executive Board changes
11th Feb 20217:00 amRNSAZN: full-year 2020 results
10th Feb 20217:00 amRNSDivestment of Crestor in Europe completed
5th Feb 20217:00 amRNSUpdate on KESTREL Phase III trial for Imfinzi
4th Feb 20217:00 amRNSForxiga approved in China for heart failure
1st Feb 20213:00 pmRNSTotal Voting Rights
1st Feb 202112:15 pmRNSAstraZeneca agrees to divest Viela shareholding
1st Feb 20217:00 amRNSCOVID-19 vaccine authorised for use by the EU
29th Jan 20213:16 pmRNSCOVID-19 vaccine receives positive opinion in EU
26th Jan 20213:00 pmRNSBlock listing application
26th Jan 20217:00 amRNSSymbicort approved in China for mild asthma
25th Jan 20217:05 amRNSCalquence approved in Japan for CLL

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.